专栏医药

WuXi AppTec posts lower profits but avoids more share price pain
药明康德利润下滑,海外业务稳定推进

The pharmaceutical services giant delivered lackluster half-year earnings, with revenues and profits both falling, but investors were relieved that its U.S. business took only a minor hit .
面对营收利润双降的药明康德2024年上半年财报,资本市场反应却相当积极。

Drug services giant WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) still faces a threatened ban on doing work for U.S. federal agencies, and its Covid-related business has taken a dive. Profits and revenues are both down, and price pressures are mounting.

作者:莫莉。本文仅代表作者观点。

您已阅读3%(266字),剩余97%(7846字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

咏竹坊

咏竹坊(官网链接)提供在香港和美国上市的manbetx3.0 企业相关新闻,重点关注中小企业和筹备上市的公司。

Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.

相关文章

相关话题

设置字号×
最小
较小
默认
较大
最大
分享×